Cytokinetics' Myqorzo Approved for Heart Condition

Cytokinetics Myqorzo, a new drug for heart condition, approved by FDA, positions it as rival to Bristol Myers Squibbs Camzyos, with fewer restrictions and potential for wider use, marking a fresh start for Cytokinetics and expanded options for heart patients.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.